Singapore-based Harvest Integrated Research Organization, known as HiRO, is making a significant move to bolster its global presence through the acquisition of Courante Oncology, a CRO (Contract Research Organization) headquartered in Minnesota with a specialized focus on oncology.
This strategic acquisition marks a pivotal milestone for HiRO as it endeavors to solidify its position as a prominent player on the global stage. While the precise financial terms of this transaction remain undisclosed, the company announced this development in a press release on August 31.
Courante Oncology, boasting over 25 years of experience in the realm of drug development, is well-versed in conducting phase 1-3 clinical trials. Their expertise spans various critical aspects of clinical research, including conducting initial feasibility studies, crafting protocols, overseeing site monitoring activities, and conducting closeout visits.
“We are thrilled to welcome Courante Oncology into the HiRO family. This acquisition allows us to leverage Courante’s extensive experience in oncology trials and enhance our capabilities in managing global studies. Together, we strive to deliver best-in-class cross-border solutions and relentless accountability that set us apart in the demanding clinical trial landscape. Our focus remains on accelerating the delivery of innovative medicines with simple, rapid, cost-effective clinical research solutions across the commercialization pathway.”
– Dr. Karen Chu, Founder and CEO of HiRO
This acquisition falls in line with the ongoing trend of consolidation within the CRO industry. In recent weeks, several other notable transactions have taken place, underscoring the dynamic nature of the clinical research landscape. These include RQM+’s acquisition of the German CRO Kottmann, Sygnature Discovery’s purchase of NuChem Sciences, Frontage Labs’ acquisition of Nucro-Technics, and Kohlberg & Co.’s acquisition of Worldwide Clinical Trials.
The expansion of HiRO’s capabilities through the addition of Courante Oncology enhances their capacity to contribute meaningfully to the advancement of oncology research and drug development on a global scale. This development signals a growing trend of collaboration and consolidation within the CRO industry as organizations seek to pool their resources and expertise to drive innovation and progress in the field of clinical research.
“This marks an exciting chapter for Courante as we join forces with HiRO. We are excited to join the HiRO family and collaborate closely with their team. This integration will enable us to further expand our service offerings and functions into the US and beyond. We look forward to collaborating with our clients, to deliver effective, streamlined clinical trial solutions that meet and exceed their expectations.”
– Sheri Smith, President of Courante Oncology
